Addex's partner discontinues adx71149 development in epilepsy

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, july 22, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner janssen pharmaceuticals, inc. (now known as j&j innovative medicine) has informed the company that it has discontinued development of adx71149 (jnj-40411813) in epilepsy.
ADXN Ratings Summary
ADXN Quant Ranking